K18 IN CLINICAL RESEARCH K18 IN CLINICAL RESEARCH K18 IN CLINICAL RESEARCH K18 IN CLINICAL RESEARCH K18 IN CLINICAL RESEARCH
Screening of Anticancer Agents in 2D and 3D cell cultures
By using the M30 Apoptosense® ELISA and the M65® ELISA, the efficacy of therapy can be demonstrated during the course of treatment. In contrast to other techniques or biomakers, which monitor tumour size and thus change slowly over the time-course of treatment, the rate of cell death is an immediate response of successful therapy indicated within hours or days from induction.
Short time elevations in caspase-cleave keratin 18 (ccK18) and total keratin 18 (K18), measured with M30 Apoptosense® ELISA and the M65® ELISA respectively, during therapy are indicative of therapy response
Persistently ccK18 and K18 levels after therapy indicate progressive disease
Relative concentrations of ccK18 and K18 provide information regarding to the mechanism of the drug, i.e. apoptosis or necrosis
Stratification of Patients
The M30 Apoptosense® ELISA and the M65® ELISA can be useful tools when assessing progression of disease and prognosis among cancer patients or study subjects, and when discriminating between healthy individuals and patients with cancer.